联合治疗矽肺结核的临床观察  

Clinical Observation of Combined therapy for Silicotuberculosis

作　　者：李孝东 李志伟 

机构地区：[1]迁西县疾控中心结防科,河北唐山064300

出　　处：《临床肺科杂志》2013年第12期2178-2178,2181,共2页Journal of Clinical Pulmonary Medicine

摘　　要：目的探讨结核化疗中加服抗痨胶囊治疗矽肺结核的临床疗效。方法选取我县结防门诊新涂阳矽肺结核病人66例,予同一方案化疗,其中32例为实验组,加服抗痨胶囊6个月。两组病人均为男性,年龄、痰菌及肺部病变无统计学差异。结果治疗二月末痰菌阴转率实验组100%(32/32),对照组82.35%(28/34)P<0.05。治疗九个月末肺部病变明显吸收好转率实验组87.5%(28/32),对照组61.76%(21/34)P<0.05。停药后两年随访,肺气肿进展率实验组15.62%(5/32),对照组(肺心病死亡1例)42.42%(14/33)P<0.05。结论实验组经化疗痰菌阴转及肺内结核病变吸收优于对照组,肺气肿进展率低于对照组。Objective To investigate the clinical effect of chemotherapy combined with anti-tuberculosis capsules in the treatment of patients with silieotuberculosis. Methods 66 patients with silieotuberculosis were randomly divided into two groups. All patients were given same chemotherapy, and 32 patients in the experiment group were additionally treated with anti-tuberculosis capsules for 6 months. Their clinical effect was analyzed and compared between the two groups. Results The negative conversion rate of sputum was 100% in the experiment group and 82.35% in the control group at the end of the second month （ P 〈 0.05 ）. The absorption rate was 87.5% in the experiment group and 61.76% in the control group （P 〈 0. 05 ）. During two years＇ follow-up, the progression rate of pulmonary emphyse- ma was 15.62% in the experiment group and 42. 42% in the control group, including 1 ease of death （ P 〈 0. 05 ）. Conclusion The clinical effect is more pronounced in the experiment group than in the control group.

关 键 词：矽肺结核 新涂阳 抗痨胶囊 化疗 肺气肿 

分 类 号：R135.2[医药卫生—劳动卫生]